173 related articles for article (PubMed ID: 32146749)
1. [Clinical characteristics and risk factors of patients with systemic lupus erythematosus and cancer].
Guo JY; Ren ZG; Xuan YY; Li TF; Liu XJ; Niu CZ; Li JY; Liu SY
Zhonghua Nei Ke Za Zhi; 2020 Mar; 59(3):218-221. PubMed ID: 32146749
[TBL] [Abstract][Full Text] [Related]
2. Arthritis and use of hydroxychloroquine associated with a decreased risk of macrophage activation syndrome among adult patients hospitalized with systemic lupus erythematosus.
Cohen EM; D'Silva K; Kreps D; Son MB; Costenbader KH
Lupus; 2018 Jun; 27(7):1065-1071. PubMed ID: 29451069
[TBL] [Abstract][Full Text] [Related]
3. The relationship between cancer and medication exposure in patients with systemic lupus erythematosus: a nested case-control study.
Guo J; Ren Z; Li J; Li T; Liu S; Yu Z
Arthritis Res Ther; 2020 Jun; 22(1):159. PubMed ID: 32586407
[TBL] [Abstract][Full Text] [Related]
4. Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies.
Li XB; Cao NW; Chu XJ; Zhou HY; Wang H; Yu SJ; Ye DQ; Li BZ
Ann Med; 2021 Dec; 53(1):1687-1695. PubMed ID: 34553648
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal Treatment Patterns and Associated Outcomes in Patients With Newly Diagnosed Systemic Lupus Erythematosus.
Kan H; Nagar S; Patel J; Wallace DJ; Molta C; Chang DJ
Clin Ther; 2016 Mar; 38(3):610-24. PubMed ID: 26907503
[TBL] [Abstract][Full Text] [Related]
6. Risk of osteonecrosis in systemic lupus erythematosus: An 11-year Chinese single-center cohort study.
Long Y; Zhang S; Zhao J; You H; Zhang L; Li J; Leng X; Wang Q; Tian X; Li M; Zeng X
Lupus; 2021 Aug; 30(9):1459-1468. PubMed ID: 34082592
[TBL] [Abstract][Full Text] [Related]
7. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.
Tsakonas E; Joseph L; Esdaile JM; Choquette D; Senécal JL; Cividino A; Danoff D; Osterland CK; Yeadon C; Smith CD
Lupus; 1998; 7(2):80-5. PubMed ID: 9541091
[TBL] [Abstract][Full Text] [Related]
8. Late-onset systemic lupus erythematosus in Latin Americans: a distinct subgroup?
Catoggio LJ; Soriano ER; Imamura PM; Wojdyla D; Jacobelli S; Massardo L; Chacón Díaz R; Guibert-Toledano M; Alvarellos A; Saurit V; Manni JA; Pascual-Ramos V; Silva de Sauza AW; Bonfa E; Tavares Brenol JC; Ramirez LA; Barile-Fabris LA; De La Torre IG; Alarcón GS; Pons-Estel BA;
Lupus; 2015 Jul; 24(8):788-95. PubMed ID: 25504653
[TBL] [Abstract][Full Text] [Related]
9. [Psoriasis and systemic lupus erythematosus: a rare association with specific therapeutic problems].
Astudillo L; Sailler L; Carreiro M; Dahan S; Ollier S; Arlet P
Ann Med Interne (Paris); 2003 Feb; 154(1):3-6. PubMed ID: 12746653
[TBL] [Abstract][Full Text] [Related]
10. [Psychiatric manifestations of lupus erythematosus systemic and Sjogren's syndrome].
Ampélas JF; Wattiaux MJ; Van Amerongen AP
Encephale; 2001; 27(6):588-99. PubMed ID: 11865567
[TBL] [Abstract][Full Text] [Related]
11. Malignancy in Systemic Lupus Erythematosus (SLE) Patients.
Cader RA; Mei Yee AK; Yassin A; Ahmad I; Haron SN
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3551-3555. PubMed ID: 30583682
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): A nationwide case-control study.
Hu SC; Yen FL; Wang TN; Lin YC; Lin CL; Chen GS
J Am Acad Dermatol; 2016 Jul; 75(1):49-58. PubMed ID: 26946984
[TBL] [Abstract][Full Text] [Related]
13. Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
Fasano S; Pierro L; Pantano I; Iudici M; Valentini G
J Rheumatol; 2017 Jul; 44(7):1032-1038. PubMed ID: 28507183
[TBL] [Abstract][Full Text] [Related]
14. Early Lupus Project - A multicentre Italian study on systemic lupus erythematosus of recent onset.
Sebastiani GD; Prevete I; Piga M; Iuliano A; Bettio S; Bortoluzzi A; Coladonato L; Tani C; Spinelli FR; Fineschi I; Mathieu A
Lupus; 2015 Oct; 24(12):1276-82. PubMed ID: 25979916
[TBL] [Abstract][Full Text] [Related]
15. Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort.
Mok CC; Tse SM; Chan KL; Ho LY
Lupus; 2018 Apr; 27(5):722-727. PubMed ID: 29087260
[TBL] [Abstract][Full Text] [Related]
16. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus.
Akhavan PS; Su J; Lou W; Gladman DD; Urowitz MB; Fortin PR
J Rheumatol; 2013 Jun; 40(6):831-41. PubMed ID: 23588942
[TBL] [Abstract][Full Text] [Related]
17. Systemic lupus erythematosus-associated acute transverse myelitis: manifestations, treatments, outcomes, and prognostic factors in 20 patients.
Saison J; Costedoat-Chalumeau N; Maucort-Boulch D; Iwaz J; Marignier R; Cacoub P; Vital-Durand D; Hot A; Tebib J; Aumaitre O; Schleinitz N; Sarrot-Reynauld F; Broussolle C; Sève P
Lupus; 2015 Jan; 24(1):74-81. PubMed ID: 25117654
[TBL] [Abstract][Full Text] [Related]
18. Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial.
Olsen NJ; James JA; Arriens C; Ishimori ML; Wallace DJ; Kamen DL; Chong BF; Liao D; Chinchilli VM; Karp DR
Trials; 2018 Dec; 19(1):694. PubMed ID: 30572906
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.
Tektonidou MG; Laskari K; Panagiotakos DB; Moutsopoulos HM
Arthritis Rheum; 2009 Jan; 61(1):29-36. PubMed ID: 19116963
[TBL] [Abstract][Full Text] [Related]
20. Systemic lupus erythematosus: review of synthetic drugs.
Tsang-A-Sjoe MW; Bultink IE
Expert Opin Pharmacother; 2015; 16(18):2793-806. PubMed ID: 26479437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
